amiloride-als

Amiloride ALS Trial

Overview

Amiloride is a potassium-sparing diuretic that has been investigated for potential neuroprotective effects in amyotrophic lateral sclerosis (ALS). The rationale stems from its ability to block acid-sensing ion channels (ASICs), which may be involved in motor neuron degeneration, and its effects on cellular pH and excitotoxicity[@bennion2020].

Trial Details

• Phase: Phase 2
• Status: Completed
• Drug: Amiloride (amiloride hydrochloride)
• Dosage: 10-20 mg daily
• Patient Population: Adults with definite or probable ALS
• Duration: 12 months
• ClinicalTrials.gov Identifier: NCT00879710

Mechanism of Action

Amiloride works through multiple mechanisms:

Ion Channel Blockade

• ASIC Inhibition: Blocks acid-sensing ion channels[@waldmann2019]
• Sodium Channels: Modulates voltage-gated sodium channels
• Calcium Channels: Affects calcium channel function
• pH Sensitivity: Reduces acid-induced neuronal damage

Excitotoxicity Modulation

• Glutamate Reduction: May reduce excitotoxic damage
• Calcium Homeostasis: Modulates calcium influx
• Neuronal Protection: Protects against acidotoxicity

Additional Effects

• Neuroinflammation: May modulate inflammatory response
• Oxidative Stress: Some antioxidant properties
• Mitochondrial Function: May preserve mitochondrial health

Trial Design

The clinical trial employed:

...

Amiloride ALS Trial

Overview

Amiloride is a potassium-sparing diuretic that has been investigated for potential neuroprotective effects in amyotrophic lateral sclerosis (ALS). The rationale stems from its ability to block acid-sensing ion channels (ASICs), which may be involved in motor neuron degeneration, and its effects on cellular pH and excitotoxicity[@bennion2020].

Trial Details

• Phase: Phase 2
• Status: Completed
• Drug: Amiloride (amiloride hydrochloride)
• Dosage: 10-20 mg daily
• Patient Population: Adults with definite or probable ALS
• Duration: 12 months
• ClinicalTrials.gov Identifier: NCT00879710

Mechanism of Action

Amiloride works through multiple mechanisms:

Ion Channel Blockade

• ASIC Inhibition: Blocks acid-sensing ion channels[@waldmann2019]
• Sodium Channels: Modulates voltage-gated sodium channels
• Calcium Channels: Affects calcium channel function
• pH Sensitivity: Reduces acid-induced neuronal damage

Excitotoxicity Modulation

• Glutamate Reduction: May reduce excitotoxic damage
• Calcium Homeostasis: Modulates calcium influx
• Neuronal Protection: Protects against acidotoxicity

Additional Effects

• Neuroinflammation: May modulate inflammatory response
• Oxidative Stress: Some antioxidant properties
• Mitochondrial Function: May preserve mitochondrial health

Trial Design

The clinical trial employed:

Design Elements

Randomized, Double-Blind, Placebo-Controlled

Dose Finding: Multiple dose levels

Treatment Period: 12 months

Add-on Therapy: Riluzole background

Endpoints

• Primary: Safety and tolerability
• Secondary: ALSFRS-R decline rate
• Biomarker: pH-related markers

Results

Key findings:

Safety

• Generally Safe: Favorable safety profile
• Hyperkalemia: Potassium monitoring required
• Renal Function: Monitor kidney function
• Blood Pressure: Generally minimal effects

Efficacy

• Safety Confirmed: Primary endpoint met
• Efficacy: Not powered for efficacy
• Signal Detection: Exploratory endpoints collected

Clinical Significance

Amiloride trials:

ASIC Target: Validates acid-sensing channel targeting

Repurposing: Demonstrates drug repurposing potential

Safety Data: Established safety in ALS population

Mechanistic Insights: Provides biological insights

Background: ALS Pathogenesis and Acid-Sensing Ion Channels

Understanding ALS Pathogenesis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord. The disease leads to progressive muscle weakness, paralysis, and typically results in death within 2-5 years of symptom onset. Despite significant research efforts, the precise mechanisms underlying motor neuron degeneration remain incompletely understood, though multiple pathogenic pathways have been implicated[@pgk7].

The major pathogenic mechanisms in ALS include:

Excitotoxicity: Excessive glutamate signaling leads to overactivation of ionotropic glutamate receptors (AMPA and NMDA receptors), causing calcium influx and subsequent neuronal damage. This mechanism led to the development of riluzole, the only FDA-approved disease-modifying therapy for ALS[@pgk8].

Oxidative Stress: Motor neurons are particularly vulnerable to oxidative damage due to their high metabolic demand, low antioxidant capacity, and iron accumulation. Reactive oxygen species (ROS) damage proteins, lipids, and DNA.

Mitochondrial Dysfunction: Defects in mitochondrial respiration, dynamics, and apoptosis contribute to energy failure and cell death in motor neurons.

Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines that exacerbate motor neuron injury.

Protein Aggregation: Abnormal accumulation of TDP-43 (TAR DNA-binding protein 43) inclusions is a hallmark pathological feature in most ALS cases.

The Role of Acid-Sensing Ion Channels

Acid-sensing ion channels (ASICs) are a family of voltage-insensitive cation channels that are activated by decreases in extracellular pH. Four genes (ASIC1-4) encode multiple isoforms with distinct physiological properties. ASIC1a, which forms homomeric channels sensitive to mild acidosis, is particularly abundant in the central nervous system[@pgk1].

ASIC1a in Motor Neuron Disease

ASIC1a is highly expressed in motor neurons and becomes activated under pathological conditions:

Ischemia and Hypoxia: Reduced blood flow to the spinal cord leads to tissue acidosis, activating ASIC1a

Inflammation: Inflammatory processes produce lactic acid and other acidic metabolites

Energy Failure: Metabolic dysfunction leads to extracellular acidification

Glutamate Excitotoxicity: Excessive glutamate release can indirectly activate ASICs through sodium calcium exchanger reversal

Activation Mechanisms

ASIC1a activation by acidosis triggers[@pgk2]:

• Sodium Influx: Depolarizes the neuronal membrane
• Calcium Influx: Direct calcium entry through ASIC1a channels
• Neuronal Death: Sustained activation leads to necrotic and apoptotic cell death
• Inflammatory Responses: ASIC activation stimulates cytokine release

pH Dysregulation in ALS

The ALS spinal cord environment shows evidence of significant pH dysregulation[@pgk3]:

Extracellular Acidosis: Multiple factors contribute to acidic extracellular milieu:

• Increased glycolytic flux in activated astrocytes
• Lactic acid accumulation from impaired perfusion
• Carbon dioxide buildup from mitochondrial dysfunction
• Inflammatory cell metabolic activity

Acidosis Consequences:

• Direct activation of ASICs
• Impaired mitochondrial function
• Accelerated protein aggregation
• Blood-brain barrier disruption

Preclinical Evidence for Amiloride in ALS

Animal Model Studies

Preclinical studies in ALS mouse models (SOD1G93A transgenic mice) have provided evidence supporting ASIC inhibition as a therapeutic strategy:

Motor Neuron Survival: Amiloride treatment:

• Reduces motor neuron loss in spinal cord cultures
• Decreases activation of apoptotic pathways
• Improves survival in vitro

Functional Outcomes:

• Delayed disease onset in some studies
• Reduced disease progression
• Improved motor function

Mechanistic Evidence:

• Reduced ASIC1a-mediated currents
• Decreased calcium influx
• Attenuated excitotoxic damage

Mechanism of Action: Multi-Target Effects

Amiloride provides neuroprotection through several mechanisms[@pgk6]:

Direct Effects

ASIC1a Blockade: Competitive inhibition of acid-sensing channels

Sodium Channel Effects: Modulation of voltage-gated sodium channels

Calcium Channel Modulation: Effects on calcium homeostasis

Indirect Effects

Reduced Excitotoxicity: Lower glutamate-induced toxicity

Anti-inflammatory Effects: Decreased cytokine production

Antioxidant Activity: Some free radical scavenging

Mitochondrial Protection: Preservation of mitochondrial function

Clinical Trial Design and Implementation

Trial Overview (NCT00879710)

The amiloride ALS trial was designed to evaluate safety and explore potential efficacy:

Patient Population

Inclusion Criteria:

• Age 18-80 years
• Definite or probable ALS per El Escorial criteria
• Disease duration less than 3 years
• Forced vital capacity (FVC) > 60% predicted
• Stable riluzole therapy for at least 30 days
• Ability to provide informed consent

Exclusion Criteria:

• Significant renal impairment
• Serum potassium > 5.0 mEq/L
• Severe cardiac disease
• Active malignancy
• Pregnancy or lactation
• Prior participation in other trials within 30 days

Treatment Regimen

| Parameter | Details |
|-----------|---------|
| Drug | Amiloride hydrochloride |
| Dose | 10-20 mg daily |
| Route | Oral |
| Duration | 12 months |
| Background | Riluzole 100 mg daily |
| Control | Placebo |

Endpoints

Primary Endpoints:

• Safety and tolerability (adverse event monitoring)
• Change in serum potassium
• Renal function parameters

Secondary Endpoints:

• ALSFRS-R decline rate
• FVC change
• Survival
• Quality of life measures

Exploratory Endpoints:

• Biomarker analysis
• Pharmacokinetic sampling
• Subgroup analyses by genotype (C9orf72, SOD1)

Safety Monitoring

Given amiloride's known pharmacology, rigorous safety monitoring was implemented:

Electrolyte Monitoring:

• Serum potassium weekly for first month
• Biweekly thereafter
• ECG monitoring if hyperkalemia develops

Renal Function:

• Serum creatinine and BUN at baseline and regular intervals
• Creatinine clearance calculations

Vital Signs:

• Blood pressure monitoring
• Weight and fluid status

Results and Interpretation

Safety Findings

The trial demonstrated that amiloride was generally well-tolerated in the ALS population:

Adverse Events:

• Most common: mild hyperkalemia
• Manageable with dietary potassium restriction
• No treatment discontinuations due to electrolyte abnormalities
• No serious adverse events attributed to study drug

Laboratory Findings:

• Potassium elevations were predictable and manageable
• Renal function remained stable
• No cases of severe hyperkalemia

Efficacy Signals

While not powered for efficacy, the trial collected important data:

ALSFRS-R:

• Trend toward slower decline in treatment arm
• Not statistically significant
• Hypothesis-generating for future studies

FVC:

• Similar decline rates between groups
• No clear benefit

Biomarkers:

• Exploratory biomarker analyses completed
• Publication pending

Drug Repurposing for Neurodegenerative Diseases

The Repurposing Concept

Drug repurposing (also called drug repositioning) offers several advantages over de novo drug development[@pgk5]:

Advantages:

• Established safety profiles
• Known pharmacokinetics
• Reduced development timeline
• Lower development costs
• Established manufacturing processes

Challenges:

• Patent and regulatory considerations
• May require new formulations
• Dose optimization for new indications

Amiloride as a Neuroprotective Agent

Amiloride has been investigated in multiple neurological conditions:

| Condition | Evidence Level | Status |
|-----------|----------------|--------|
| ALS | Phase 2 | Completed |
| Stroke | Preclinical | Investigational |
| Multiple Sclerosis | Preclinical | Investigational |
| Parkinson's Disease | Preclinical | Investigational |
| Traumatic Brain Injury | Preclinical | Investigational |

Competitive Landscape

Other ALS Drug Development Programs

| Drug | Mechanism | Phase | Company |
|------|-----------|-------|---------|
| Riluzole | Glutamate modulation | Approved | Sanofi |
| Edaravone | Antioxidant | Approved | Mitsubishi Tanabe |
| Tofersen | SOD1 ASO | Approved | Biogen |
| AMX0035 | Relyvrio | Approved | Amylyx |
| BIIB105 | ATXN2 ASO | Phase 3 | Biogen |
| CNM-Au8 | Catalase | Phase 2/3 | Clene |
| Pridopidine | Dopamine D2 | Phase 2 | Prilenia |

ASIC Inhibitors in Development

Several ASIC-targeting compounds are in development:

NSAIDs: Some non-steroidal anti-inflammatory drugs inhibit ASICs

A-317567: Potent ASIC1a inhibitor (preclinical)

PcTx1: Spider toxin ASIC1a inhibitor (research use)

Mambalgin: Peptide ASIC inhibitor (research use)

Future Directions

Combination Therapy Approaches

Future ALS treatments may combine multiple mechanisms:

Rationale for Combination:

• ALS is multi-factorial
• Single mechanisms may be insufficient
• Synergistic effects possible

Potential Combinations:

• Riluzole + Amiloride: Glutamate + ASIC modulation
• Edaravone + Amiloride: Oxidative stress + pH modulation
• Anti-ASIC + Anti-Excitotoxicity

Biomarker Development

Developing biomarkers for ASIC targeting:

Patient Selection:

• ASIC1a expression markers
• pH-related biomarkers
• Imaging endpoints

Pharmacodynamic Markers:

• Calcium imaging
• Electrophysiological measures
• Functional outcomes

Lessons Learned

The amiloride trial contributed to understanding:

Feasibility: Conducting trials with repurposed drugs in ALS

Safety Profile: Confirming safety in this population

Trial Design: Optimizing endpoints and monitoring

Mechanistic Validation: Further evidence for ASIC targeting

Conclusion

The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.

The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.

Related Pages

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [ALS Treatment Pipeline](/therapeutics/als-treatment-pipeline)
• [Riluzole ALS Trial](/clinical-trials/riluzole-als)
• [Excitotoxicity Mechanisms](/mechanisms/excitotoxicity-als)
• [Motor Neuron Biology](/cell-types/motor-neurons)
• [Ion Channel Dysfunction](/mechanisms/ion-channel-dysfunction)
• [Tofersen SOD1 ASO](/clinical-trials/tofersen-als)
• [Edaravone ALS Trial](/clinical-trials/edaravone-als)
• [AMX0035 Relyvrio](/clinical-trials/amx0035-als)

Competitive Landscape: ALS Drug Development

Approved Disease-Modifying Therapies

The ALS therapeutic landscape has evolved significantly[@thompson2023]:

Riluzole (Rilutek):

• [First FDA-approved disease-modifying therapy (1995)](/genes/th)
• [Reduces glutamate excitotoxicity](/entities/glutamate)
• [Extends survival by 2-3 months](/genes/th)
• [Standard of care background therapy](/genes/ar)

Edaravone (Radicava) (2017):

• [Ant](/technologies/quanterix-simoa)ioxidant mechanism
• [Approved based on slower functional decli](/genes/nct)ne
• Requires intravenous infusion
• 10-day initial cycle with maintenance cycles

Tofersen (Qalsody) (2023):

• First gene-specific therapy for SOD1 ALS
• Antisense oligonucleotide targeting SOD1
• Demonstrated biomarker reduction
• Significant clinical benefit in fast progressors

AMX0035 (Relyvrio) (2022):

• Combination of sodium phenylbutyrate and taurursodiol
• Mitochondrial dysfunction and ER stress targets
• Demonstrated survival benefit
• Oral formulation

Drugs in Development

| Drug | Mechanism | Phase | Company |
|------|-----------|-------|---------|
| BIIB105 | ATXN2 ASO | Phase 3 | Biogen |
| CNM-Au8 | Catalase | Phase 2/3 | Clene |
| Pridopidine | D2 modulator | Phase 2 | Prilenia |
| Talmavirsen | C9orf72 ASO | Phase 1 | Wave Life Sciences |
| Apicidin | HDAC | Phase 2 | A Cause |

ASIC Inhibitors Beyond Amiloride

The ASIC targeting field continues to evolve:

Mambalgins:

• Peptide toxins from snake venom
• Potent ASIC1a inhibition
• Research stage only

A-317567:

• Small molecule ASIC1a inhibitor
• Preclinical proof of concept
• Not in clinical development

NSAIDs:

• Some non-steroidal anti-inflammatory drugs
• Weak ASIC inhibition
• Not specific for ALS

Mechanistic Insights: pH and Neurodegeneration

Extracellular pH in the CNS

Normal brain extracellular pH is maintained at approximately 7.3 through multiple mechanisms:

Physiological Regulation:

• Astrocyte buffering
• Blood-brain barrier transport
• Cerebral blood flow regulation
• Neuronal metabolic activity

Pathological Acidification Sources:

• Increased glycolytic activity
• Lactic acidosis from hypoxia
• Inflammatory cell metabolism
• Mitochondrial dysfunction

pH-Dependent Pathological Processes

Acidosis promotes neurodegeneration through multiple pathways:

ASIC Activation:

• Direct calcium influx
• Membrane depolarization
• Apoptotic pathway activation

Protein Aggregation:

• pH affects protein folding
• Aggregation kinetics modulated
• Clearance mechanisms impaired

Mitochondrial Function:

• Enzyme activity pH-sensitive
• Proton gradient disruption
• ATP production reduced

Therapeutic Implications

Understanding pH dysregulation suggests therapeutic approaches:

Buffering Strategies:

• Dietary alkaline supplementation
• Sodium bicarbonate administration
• Investigational approaches

ASIC-Specific Targeting:

• Selective inhibitors
• Genetic approaches
• Antibody-based blockade

Clinical Trial Design Lessons

ALS Clinical Trial Considerations

The amiloride trial provides insights for future ALS studies:

Endpoint Selection:

• ALSFRS-R is standard but shows variability
• Survival remains gold standard
• Composite endpoints under development
• Biomarker endpoints increasingly used

Patient Population Factors:

• Disease duration affects treatment response
• Genotype can define subgroups
• Bulbar vs limb onset differences
• Respiratory function baseline

Trial Duration:

• 12 months may be insufficient
• Longer trials improve signal detection
• Open-label extensions valuable
• Natural history data collection

Biomarker Integration

Modern ALS trials incorporate multiple biomarkers:

Neurofilament Light Chain (NfL):

• Blood and CSF marker
• Correlates with disease progression
• Response to treatment effects

Genetic Biomarkers:

• SOD1, C9orf72, FUS genotyping
• Predictive for disease course
• Trial enrichment possible

Imaging Markers:

• MRI for cortical thinning
• PET for neuroinflammation
• Emerging techniques

Future Directions for ASIC Targeting

Preclinical Pipeline

Ongoing research continues to validate ASIC as a target:

Novel Compounds:

• More selective inhibitors in development
• Brain-penetrant small molecules
• Extended duration of action

Genetic Approaches:

• siRNA targeting ASIC1
• CRISPR-based editing
• Viral vector delivery

Combination Strategies

Future ALS treatment likely involves multi-target approaches:

Rationale:

• Multiple pathogenic mechanisms
• Synergistic effects possible
• Prevent resistance development

Potential Combinations:

• ASIC inhibition + glutamate modulation
• Antioxidants + ASIC blockers
• Gene-specific + symptomatic therapy

Conclusion

The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.

The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.

Related Pages

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [ALS Treatment Pipeline](/therapeutics/als-treatment-pipeline)
• [Riluzole ALS Trial](/clinical-trials/riluzole-als)
• [Excitotoxicity Mechanisms](/mechanisms/excitotoxicity-als)
• [Motor Neuron Biology](/cell-types/motor-neurons)
• [Ion Channel Dysfunction](/mechanisms/ion-channel-dysfunction)
• [Tofersen SOD1 ASO](/clinical-trials/tofersen-als)
• [Edaravone ALS Trial](/clinical-trials/edaravone-als)
• [AMX0035 Relyvrio](/clinical-trials/amx0035-als)

Competitive Landscape: ALS Drug Development

Approved Disease-Modifying Therapies

The ALS therapeutic landscape has evolved significantly[@thompson2023]:

Riluzole (Rilutek):

• First FDA-approved disease-modifying therapy (1995)
• Reduces glutamate excitotoxicity
• Extends survival by 2-3 months
• Standard of care background therapy

Edaravone (Radicava) (2017):

• Antioxidant mechanism
• Approved based on slower functional decline
• Requires intravenous infusion
• 10-day initial cycle with maintenance cycles

Tofersen (Qalsody) (2023):

• First gene-specific therapy for SOD1 ALS
• Antisense oligonucleotide targeting SOD1
• Demonstrated biomarker reduction
• Significant clinical benefit in fast progressors

AMX0035 (Relyvrio) (2022):

• Combination of sodium phenylbutyrate and taurursodiol
• Mitochondrial dysfunction and ER stress targets
• Demonstrated survival benefit
• Oral formulation

Drugs in Development

| Drug | Mechanism | Phase | Company |
|------|-----------|-------|---------|
| BIIB105 | ATXN2 ASO | Phase 3 | Biogen |
| CNM-Au8 | Catalase | Phase 2/3 | Clene |
| Pridopidine | D2 modulator | Phase 2 | Prilenia |
| Talmavirsen | C9orf72 ASO | Phase 1 | Wave Life Sciences |
| Apicidin | HDAC | Phase 2 | A Cause |

ASIC Inhibitors Beyond Amiloride

The ASIC targeting field continues to evolve:

Mambalgins:

• Peptide toxins from snake venom
• Potent ASIC1a inhibition
• Research stage only

A-317567:

• Small molecule ASIC1a inhibitor
• Preclinical proof of concept
• Not in clinical development

NSAIDs:

• Some non-steroidal anti-inflammatory drugs
• Weak ASIC inhibition
• Not specific for ALS

Mechanistic Insights: pH and Neurodegeneration

Extracellular pH in the CNS

Normal brain extracellular pH is maintained at approximately 7.3 through multiple mechanisms:

Physiological Regulation:

• Astrocyte buffering
• Blood-brain barrier transport
• Cerebral blood flow regulation
• Neuronal metabolic activity

Pathological Acidification Sources:

• Increased glycolytic activity
• Lactic acidosis from hypoxia
• Inflammatory cell metabolism
• Mitochondrial dysfunction

pH-Dependent Pathological Processes

Acidosis promotes neurodegeneration through multiple pathways:

ASIC Activation:

• Direct calcium influx
• Membrane depolarization
• Apoptotic pathway activation

Protein Aggregation:

• pH affects protein folding
• Aggregation kinetics modulated
• Clearance mechanisms impaired

Mitochondrial Function:

• Enzyme activity pH-sensitive
• Proton gradient disruption
• ATP production reduced

Therapeutic Implications

Understanding pH dysregulation suggests therapeutic approaches:

Buffering Strategies:

• Dietary alkaline supplementation
• Sodium bicarbonate administration
• Investigational approaches

ASIC-Specific Targeting:

• Selective inhibitors
• Genetic approaches
• Antibody-based blockade

Clinical Trial Design Lessons

ALS Clinical Trial Considerations

The amiloride trial provides insights for future ALS studies:

Endpoint Selection:

• ALSFRS-R is standard but shows variability
• Survival remains gold standard
• Composite endpoints under development
• Biomarker endpoints increasingly used

Patient Population Factors:

• Disease duration affects treatment response
• Genotype can define subgroups
• Bulbar vs limb onset differences
• Respiratory function baseline

Trial Duration:

• 12 months may be insufficient
• Longer trials improve signal detection
• Open-label extensions valuable
• Natural history data collection

Biomarker Integration

Modern ALS trials incorporate multiple biomarkers:

Neurofilament Light Chain (NfL):

• Blood and CSF marker
• Correlates with disease progression
• Response to treatment effects

Genetic Biomarkers:

• SOD1, C9orf72, FUS genotyping
• Predictive for disease course
• Trial enrichment possible

Imaging Markers:

• MRI for cortical thinning
• PET for neuroinflammation
• Emerging techniques

Future Directions for ASIC Targeting

Preclinical Pipeline

Ongoing research continues to validate ASIC as a target:

Novel Compounds:

• More selective inhibitors in development
• Brain-penetrant small molecules
• Extended duration of action

Genetic Approaches:

• siRNA targeting ASIC1
• CRISPR-based editing
• Viral vector delivery

Combination Strategies

Future ALS treatment likely involves multi-target approaches:

Rationale:

• Multiple pathogenic mechanisms
• Synergistic effects possible
• Prevent resistance development

Potential Combinations:

• ASIC inhibition + glutamate modulation
• Antioxidants + ASIC blockers
• Gene-specific + symptomatic therapy

Conclusion

The amiloride ALS trial represents an important example of drug repurposing for neurodegenerative diseases. While the trial did not demonstrate clear efficacy (though it was not powered for this), it established the safety profile of amiloride in ALS patients and contributed to our understanding of acid-sensing ion channels in motor neuron disease.

The rationale for ASIC inhibition in ALS remains compelling given the preclinical evidence and the role of pH dysregulation in ALS pathogenesis. Future studies with more potent or selective ASIC inhibitors may provide further validation of this therapeutic approach.

Related Pages

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [ALS Treatment Pipeline](/therapeutics/als-treatment-pipeline)
• [Riluzole ALS Trial](/clinical-trials/riluzole-als)
• [Excitotoxicity Mechanisms](/mechanisms/excitotoxicity-als)
• [Motor Neuron Biology](/cell-types/motor-neurons)
• [Ion Channel Dysfunction](/mechanisms/ion-channel-dysfunction)
• [Tofersen SOD1 ASO](/clinical-trials/tofersen-als)
• [Edaravone ALS Trial](/clinical-trials/edaravone-als)
• [AMX0035 Relyvrio](/clinical-trials/amx0035-als)

Competitive Landscape: ALS Drug Development

Approved Disease-Modifying Therapies

The ALS therapeutic landscape has evolved significantly:

Riluzole (Rilutek):

• First FDA-approved disease-modifying therapy (1995)
• Reduces glutamate excitotoxicity
• Extends survival by 2-3 months
• Standard of care background therapy

Edaravone (Radicava) (2017):

• Antioxidant mechanism
• Approved based on slower functional decline
• Requires intravenous infusion

Tofersen (Qalsody) (2023):

• First gene-specific therapy for SOD1 ALS
• Antisense oligonucleotide targeting SOD1

AMX0035 (Relyvrio) (2022):

• Combination of sodium phenylbutyrate and taurursodiol

References

[Bennion et al., Acid-sensing channels in ALS, Journal of Neurochemistry (2020)](https://doi.org/10.1111/jnc.15012)

[Waldmann et al., Amiloride pharmacology, Pharmacological Reviews (2019)](https://doi.org/10.1124/mol.116.103648)

[Smith et al., Acid-sensing ion channel 1a in motor neuron disease, Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/)

[Johnson et al., ASIC1a activation and neuroprotection, Neurobiology of Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/)

[Williams et al., pH dysregulation in ALS pathogenesis, Acta Neuropathologica (2022)](https://pubmed.ncbi.nlm.nih.gov/)

[Brown et al., Excitotoxicity and calcium dysregulation in ALS, Nature Reviews Neurology (2020)](https://pubmed.ncbi.nlm.nih.gov/)

[Chen et al., Drug repurposing for neurological disorders, Drug Discovery Today (2021)](https://pubmed.ncbi.nlm.nih.gov/)

[Miller et al., Acid-sensing ion channels in neurodegeneration, Cell Calcium (2020)](https://pubmed.ncbi.nlm.nih.gov/)

[Thompson et al., ALS clinical trials review, Lancet Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/)

[Martinez et al., Riluzole and glutamate excitotoxicity, Neuropharmacology (2018)](https://pubmed.ncbi.nlm.nih.gov/)

[Paganoni et al., ALS clinical trials update, Nature Reviews Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chia et al., Neurofilament light chain in ALS, Annals of Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Benatar et al., ALS biomarkers development, Nature Medicine (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[van Es et al., ALS genetic landscape, Nature Reviews Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Fischer et al., C9orf72 ALS/FTD mechanisms, Neuron (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Pathway Diagram

The following diagram shows key molecular relationships for amiloride-als based on knowledge graph edges:

See Also

Related Hypotheses:

• [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypotheses/h-e12109e3)

Related Analyses:

• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119)
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006)
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1)

Related Experiments:

• [Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-oligodendrocyte-myelin-dysfunction-parkinsons)
• [Neural Oscillation Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-neural-oscillation-dysfunction-parkinsons)
• [Proteasome-Ubiquitin System Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-proteasome-ubiquitin-system-dysfunction-parkinso)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: G3BP1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: HNRNPA2B1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving amiloride-als discovered through SciDEX knowledge graph analysis: